Funds holding MapLight Therapeutics Inc
ISIN US56565P1030 · United States
- Fund holders
- 104
- Of which ETFs
- 17 87 other funds
- Value held
- 92.1M $
- Share of capital
- 10.1 % of 42.4M shares on Mar 19, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| Russell 2000 1.5x Strategy Fund Rydex Series Funds | 23 | 467.6 $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
| ProShares Hedge Replication ETF ProShares Trust | 17 | 293.6 $ | 0.00 % | 0.00 % | as of Feb 28, 2026 ↗ |
| ProShares Russell 2000 Dynamic Buffer ETF ProShares Trust | 7 | 120.9 $ | 0.01 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Russell 2000(R) 1.5x Strategy Fund Rydex Variable Trust | 4 | 81.3 $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| CapForce IBD Breakout Opportunities ETF Capital Force ETF Trust | 2.27 % | as of Apr 30, 2026 ↗ |
| Lazard Retirement US Small Cap Equity Select Portfolio LAZARD RETIREMENT SERIES INC | 0.84 % | as of Mar 31, 2026 ↗ |
| Lazard US Small Cap Equity Select Portfolio LAZARD FUNDS INC | 0.83 % | as of Mar 31, 2026 ↗ |
| Lazard Global Small Cap Equity Portfolio LAZARD FUNDS INC | 0.74 % | as of Mar 31, 2026 ↗ |
| Janus Henderson Small Cap Growth Alpha ETF Janus Detroit Street Trust | 0.52 % | as of Apr 30, 2026 ↗ |
| T. Rowe Price Health Care ETF T. Rowe Price Exchange-Traded Funds, Inc. | 0.51 % | as of Mar 31, 2026 ↗ |
| iShares Neuroscience and Healthcare ETF iShares Trust | 0.42 % | as of Apr 30, 2026 ↗ |
| Fidelity Advisor Biotechnology Fund Fidelity Advisor Series VII | 0.34 % | as of Apr 30, 2026 ↗ |
| T. Rowe Price Institutional Small-Cap Stock Fund T. Rowe Price Equity Funds, Inc. | 0.16 % | as of Mar 31, 2026 ↗ |
| T. Rowe Price Small-Cap Stock Fund, Inc. T. ROWE PRICE SMALL-CAP STOCK FUND, INC. | 0.16 % | as of Mar 31, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Holders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 104 | +26 | 4,265,534 | +36.1 % |
| 2026Q1 | 78 | +77 | 3,133,039 | +199,966.3 % |
| 2025Q4 | 1 | 1,566 |
Institutional managers
77 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| NOVO HOLDINGS A/S | 3,686,622 | 74.9M $ | as of Mar 31, 2026 |
| FCPM III SERVICES B.V. | 3,226,400 | 65.6M $ | as of Mar 31, 2026 |
| T. Rowe Price Investment Management, Inc. | 2,801,937 | 57K $ | as of Mar 31, 2026 |
| GOLDMAN SACHS GROUP INC | 1,994,873 | 40.6M $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 1,339,731 | 27.2M $ | as of Mar 31, 2026 |
| Blue Owl Capital Holdings LP | 1,005,929 | 20.5M $ | as of Mar 31, 2026 |
| Nan Fung Group Holdings Ltd | 971,253 | 19.7M $ | as of Mar 31, 2026 |
| 5AM Venture Management, LLC | 950,011 | 19.3M $ | as of Mar 31, 2026 |
| Sanofi | 912,041 | 18.5M $ | as of Mar 31, 2026 |
| Pivotal bioVenture Partners Investment Advisor LLC | 611,447 | 12.4M $ | as of Mar 31, 2026 |
| Velan Capital Investment Management LP | 492,893 | 10M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 481,201 | 9.8M $ | as of Mar 31, 2026 |
| Siren, L.L.C. | 450,000 | 9.1M $ | as of Mar 31, 2026 |
| Vestal Point Capital, LP | 420,000 | 8.5M $ | as of Mar 31, 2026 |
| ADAR1 Capital Management, LLC | 374,909 | 7.6M $ | as of Mar 31, 2026 |
| BAKER BROS. ADVISORS LP | 364,705 | 7.4M $ | as of Mar 31, 2026 |
| STATE STREET CORP | 339,116 | 6.9M $ | as of Mar 31, 2026 |
| Freestone Grove Partners LP | 313,957 | 6.4M $ | as of Mar 31, 2026 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 267,746 | 5.4M $ | as of Mar 31, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 248,294 | 5M $ | as of Mar 31, 2026 |
| UBS Group AG | 236,512 | 4.8M $ | as of Mar 31, 2026 |
| FMR LLC | 204,501 | 4.2M $ | as of Mar 31, 2026 |
| Board of Trustees of The Leland Stanford Junior University | 199,231 | 4.1M $ | as of Mar 31, 2026 |
| SUPERSTRING CAPITAL MANAGEMENT LP | 192,139 | 3.9M $ | as of Mar 31, 2026 |
| DAFNA Capital Management LLC | 171,006 | 3.5M $ | as of Mar 31, 2026 |
Declared shareholders of MapLight Therapeutics Inc
There is 1 beneficial ownership filing. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 7.40 % | 3,137,558 | as of Mar 31, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Funds holding MapLight Therapeutics Inc". https://titelia.com/en/stocks/maplight-therapeutics-inc-US56565P1030